Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Post by wallpaper2on Oct 23, 2023 12:21pm
224 Views
Post# 35696491

Dart

DartYou were the self appointed  expert on MLCL and posted around 1000X per year. It is bankrupt and  HALTED at .005 cents and you predicted dollar$ .
IPA wil see $5-$20/share before it ever hits your Pink Sheet exchange. We will see who is right in a few short months.
IPA:  Nasdaq stock with only 25 million shares outstanding and a strong revenue  stream already.  Proving to be  the worlds  #1 Biotherapeutic AI Company.. No major news until January at the earliest. New Board of Directors coming onboard  with major backing from Wall St Bankers and Fund Managers.  Cheers.
<< Previous
Bullboard Posts
Next >>